Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Matrix metalloproteinase-19 (MMP-19) fluorometric drug discovery kit, RED

 
BML-AK307-0001 96 wells 525.00 USD
Do you need bulk/larger quantities?
 
The MMP-19 Fluorometric (also known as fluorimetric) Drug Discovery Kit, RED is a complete assay system designed to screen MMP-19 inhibitors using a quenched fluorogenic substrate OMNIMMP® RED: TQ3-GABA-Pro-Cha-Abu-Smc-His-Ala-Dab(6-TAMRA)-Ala-Lys-NH2 [TQ3=quencher; GABA=4-aminobutyric acid; Cha=L-cyclohexylalanine; Abu=2-aminobutyric acid; Smc=S-methyl-L-cysteine; Dab=2,4-diaminobutyric acid; 6-TAMRA=6-tetramethylrhodamine]. TAMRA fluorescence is thoroughly quenched by the TQ3 group until cleavage by MMPs separates the two moieties.

The assays are performed in a convenient 96-well microplate format. The kit is useful to screen inhibitors of MMP-19, a potential therapeutic target. The compound NNGH is also included as a prototypic control inhibitor.

Product Specification

Alternative Name:RASI
 
Applications:Fluorescent detection, HTS
Activity assay
 
Application Notes:Designed to screen MMP-19 inhibitors using a quenched fluorogenic peptide.
 
Handling:Avoid freeze/thaw cycles.
 
Shipping:Shipped on Dry Ice
 
Long Term Storage:-80°C
 
Kit/Set Contains:1 vial MMP-19 enzyme
1 vial Substrate (OMNIMMP® RED)
1 vial 6’-TAMRA calibration standard
1 vial control inhibitor (NNGH)
1 bottle (20 ml) assay buffer
1 black 96-well microplate
Instructions
 
Scientific Background:Matrix metalloproteinase-19 (MMP-19, RASI; was initially named MMP-181) is a member of the MMP family of extracellular proteases.  These enzymes play a role in many normal and disease states by virtue of their broad substrate specificities. Targets of MMP-19 include aggrecan, fibronectin, type I gelatin, and basement membrane components such as laminin, nidogen, and type IV collagen. MMP-19 is an important target for inhibitor screening due to its involvement in diseases such as angiogenesis, cancer, rheumatoid arthritis, multiple sclerosis, and psoriasis.
 
Technical Info/Product Notes:NCBI Reference Sequence: NM_002429

The OMNIMMP® RED substrate offers key advantages over other MMP substrates.
  1. Emission at the red end of the spectrum (576 nm after excitation at 545 nm) avoids the interference at lower wavelengths often exhibited by screening compounds, and by substances commonly found in biological samples and tissue culture medium.
  2. MMP substrate peptides display poor aqueous solubility, often with Kms near their limits of solubility, making enzyme and inhibitor kinetics difficult. MMP Kms for OMNIMMP® RED substrate are below its solubility limit.
  3. In addition to the efficient binding as exhibited by low Kms, OMNIMMP® RED is avidly cleaved by MMPs, with kcat/Kms in the range of 104-106 M-1sec-1.
  4. The ultra-strong fluorescence of OMNIMMP® RED allows for substrate concentrations much lower than the Km, a condition generally desirable in inhibitor screening assays.
 
UniProt ID:Q99542
 

General Literature References

Matrix metalloproteinases: regulators of the tumor microenvironment: K. Kessenbrock & Z. Werb; Cell 141, 52 (2010), Abstract;
MMP19 is upregulated during melanoma progression and increases invasion of melanoma cells: M. Muller, et al.; Mod. Pathol. 23, 511 (2010), Abstract;
Updated biological roles for matrix metalloproteinases and new "intracellular" substrates revealed by degradomics : G.S. Butler & C.M. Overall; Biochemistry 48, 10830 (2009), Abstract;
VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE: W.A. Roscoe, et al.; J. Neuroimmunol. 209, 6 (2009), Abstract;
Matrix metalloproteinase 19 is highly expressed in active multiple sclerosis lesions: J. van Horssen, et al.; Neuropathol. Appl. Neurobiol. 32, 585 (2006), Abstract;
Matrix metalloproteinase-19 is expressed by keratinocytes in psoriasis: J. van Horssen, et al.; Acta Derm. Venereol. 83, 108 (2003),
Matrix metalloproteinases: they're not just for matrix anymore!: L.J. McCawley & L.M. Matrisian; Curr. Opin. Cell Biol. 13, 534 (2001), Abstract;
Biochemical characterization of the catalytic domain of human matrix metalloproteinase 19. Evidence for a role as a potent basement membrane degrading enzyme: J.O. Stracke, et al.; J. Biol. Chem. 275, 14809 (2000), Abstract;
Matrix metalloproteinases 19 and 20 cleave aggrecan and cartilage oligomeric matrix protein (COMP): J.O. Stracke, et al.; FEBS Lett. 478, 52 (2000), Abstract;
Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits: L.J. MacPherson, et al.; J. Med. Chem. 40, 2525 (1997), Abstract;
Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution: A.M. Pendas, et al.; J. Biol. Chem. 272, 4281 (1997), Abstract;
The matrix metalloproteinase RASI-1 is expressed in synovial blood vessels of a rheumatoid arthritis patient: C. Kolb, et al.; Immunol. Lett. 57, 83 (1997), Abstract;
Identification of MMP-18, a putative novel human matrix metalloproteinase: J. Cossins, et al.; Biochem. Biophys. Res. Commun. 228, 494 (1996), Abstract;

Product Toolbox

PRODUCT RESOURCES

Datasheet
MSDS
Certificate of Analysis
Manual

RELATED PRODUCTS

By target:
MMP
By biological activity:
MMP Activity kit
By catalog section:

PRODUCT SUPPORT

FAQs
Technical Service
Customer Service

Related Literature

Brochures
Stem Cells
Stem Cells
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,